Astrazeneca news from FiercePharma
NewsBMS: Buyer or buyout target?
Market-watchers love to speculate. Their latest topic? Bristol-Myers Squibb, which has been paring away its "non-core" businesses over the last few months. Most recently, Bristol agreed to Read more...
AZ stock falls on Symbicort patent loss
What a difference one patent ruling can make. AstraZeneca lost almost $1.3 billion in market value today after announcing that the European Patent Office yanked a patent covering its blockbuster Read more...
U.K. kids' antipsychotic use doubled
The number of U.K. kids taking antipsychotics has doubled in recent years, expert say, as use of the meds has broadened to hyperactive and autistic children. The increase was most marked among 7- to Read more...
Drugmakers fighting for best U.K. deal
As the U.K. nears a long-term drug-pricing deal with pharma firms, drugmakers are grousing about the fact that the government decided to renegotiate at all. You'll recall that late last year, the Read more...
AZ reaffirms whole-hog API outsourcing
Remember last fall when AstraZeneca EVP David Smith said the company was looking to outsource most of its Read more...
SPOTLIGHT: AstraZeneca wants FDA ad review
AstraZeneca is lobbying Congress for FDA review of television ads. Last fall lawmakers created a program that would require up-front scrutiny of DTC ads, but didn't give the FDA authority to collect Read more...
AZ, Amgen earnings flat; Shire sales leap
It's a mixed bag of drugmaker earnings reports today, with two biggies posting flat results and two smaller firms chalking up respectable gains.AstraZeneca's profits suffered under restructuring Read more...
ALSO NOTED: Genzyme can't make Myozyme at Boston plant; Ranbaxy, Orchid forge drug-and-API deal;
> FDA won't let Genzyme make its uber-expensive Pompe disease treatment Myozyme at its Boston plant because of a small difference between the batches of Myozyme Genzyme makes now and the new Read more...
Pharma fighting back in Washington
Call it the backlash against the backlash. In the wake of the recent Read more...
Emerging markets drive global growth
Without emerging healthcare markets like China and India, global pharma would be in a world of hurt. The global market for meds reached $712 billion last year, according to a new report from IMS Read more...
| Press ReleasesPRESS RELEASE: AstraZeneca Files Patent Infringement Actions in Response to Crestor™ ANDAs AstraZeneca Files Patent Infringement Actions in Response to Crestor™ ANDAs AstraZeneca today announced that it has filed patent infringement actions in United States District Court, District of Read more... PRESS RELEASE: FDA's Safety Reviews of Prilosec and Nexium Find No Evidence of Increased Rates of Cardiac Events FDA's Safety Reviews of Prilosec and Nexium Find No Evidence of Increased Rates of Cardiac Events Background: On May 29, 2007 AstraZeneca, the maker of Prilosec (omeprazole) and Nexium Read more... PRESS RELEASE: AstraZeneca Presents its Global Biologics Organisation, MedImmune, at 2007 Analyst and Investor R&D Day AstraZeneca Presents its Global Biologics Organisation, MedImmune, at 2007 Analyst and Investor R&D Day AstraZeneca (AZN) today holds an R&D day for analysts and investors at the Read more... PRESS RELEASE: AstraZeneca Presents New Depression and Anxiety Results for SEROQUEL AstraZeneca Presents New Depression and Anxiety Results for SEROQUEL The first data from the SEROQUEL XR™ (quetiapine fumarate) Extended Release clinical development programme in major depressive Read more... PRESS RELEASE: AstraZeneca Receives Six Months Paediatric Exclusivity Patent Extension For ARIMIDEX From The FDA AstraZeneca Receives Six Months Paediatric Exclusivity Patent Extension For ARIMIDEX From The FDA AstraZeneca today announced that the United States (US) Food and Drug Administration (FDA) has Read more... |
Get more Astrazeneca coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight